Cargando…

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

Detalles Bibliográficos
Autores principales:	Hifumi, Toru, Isokawa, Shutaro, Otani, Norio, Ishimatsu, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422471/ https://www.ncbi.nlm.nih.gov/pubmed/32787901 http://dx.doi.org/10.1186/s13054-020-03227-4

Ejemplares similares

The application of 6S in the care of COVID-19 patients: a Japanese perspective
por: Soh, Mitsuhito, et al.
Publicado: (2020)

Neuroleptic malignant syndrome in patients with COVID-19
por: Soh, Mitsuhito, et al.
Publicado: (2020)

The authors' response: Propofol in COVID 19: From basic science to clinical impact()
por: Soh, Mitsuhito, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Man with severe COVID pneumonia
por: Isokawa, Shutaro, et al.
Publicado: (2020)

The authors’ response: Propofol and sedation in patients with coronavirus disease 2019
por: Soh, Mitsuhito, et al.
Publicado: (2021)

The authors' response: A diagnostic confusion between serotonin syndrome and neuroleptic malignant syndrome
por: Soh, Mitsuhito, et al.
Publicado: (2021)

Persistent Air Embolism after Blunt Chest Trauma with Recovery to Pre-Existing Consciousness Level: A Case Report and Literature Review
por: Soh, Mitsuhito, et al.
Publicado: (2022)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Empyema with fistula successfully treated with a comprehensive approach including bronchial blocker and embolization receiving veno‐venous extracorporeal membrane oxygenation
por: Shin, Kijong, et al.
Publicado: (2021)

Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave
por: Banno, Aya, et al.
Publicado: (2021)

Association between inflammation in acute phase and early onset pneumonia in patients with out‐of‐hospital cardiac arrest treated with extracorporeal cardiopulmonary resuscitation
por: Shiba, Daiki, et al.
Publicado: (2020)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
por: Osawa, Itsuki, et al.
Publicado: (2020)

Postintensive Care Syndrome-Family Associated With COVID-19 Infection
por: Shirasaki, Kasumi, et al.
Publicado: (2022)

One-Year Outcomes of Postintensive Care Syndrome in Critically Ill Coronavirus Disease 2019 Patients: A Single Institutional Study
por: Banno, Aya, et al.
Publicado: (2021)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Impaired mental health status following intensive care unit admission in a patient with COVID‐19
por: Soh, Mitsuhito, et al.
Publicado: (2020)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Tokyo and New York: A Study in the Contrasting Effects of Socioeconomic Status on Coronavirus Disease 2019 Outcomes
por: Hifumi, Toru, et al.
Publicado: (2020)

Rapid influenza diagnostic test at triage can decrease emergency department length of stay
por: Iwasaki, Tsutomu, et al.
Publicado: (2020)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Relationship Between the Number of Patients Visiting Emergency Department and Tokyo Health System’s Capacity During Early Stages of the First Wave of COVID-19
por: Ishikawa, Yohei, et al.
Publicado: (2020)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Moon, Kyunglan, et al.
Publicado: (2021)

Development of acute kidney injury with massive granular casts and microscopic hematuria in patients with COVID-19: two case presentations with literature review
por: Fujimaru, Takuya, et al.
Publicado: (2020)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Pneumonia and Extracorporeal Cardiopulmonary Resuscitation Followed by Targeted Temperature Management in Patients With Out-of-Hospital Cardiac Arrest　― Retrospective Cohort Study ―
por: Shiba, Daiki, et al.
Publicado: (2019)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

Frequency, clinical characteristics, and outcomes of pneumonia in patients with out-of-hospital cardiac arrest undergoing extracorporeal cardiopulmonary resuscitation()
por: Iida, Eiki, et al.
Publicado: (2023)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Anaphylactic Reactions Caused by Nafamostat Mesylate during Hemodialysis before Surgery for Carpal Tunnel Syndrome
por: Nakamura, Yuta, et al.
Publicado: (2021)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
por: Kim, Hyeon-A, et al.
Publicado: (2022)

Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition
por: Morimoto, Mari, et al.
Publicado: (2022)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
por: Zhang, Yuxin, et al.
Publicado: (2020)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lqkcj04t5h6mtr8qndlon280vg